Navigation Links
SafeCode Drug Technologies to Hire Project Manager to Market FDA Approved Painless Injection Device
Date:4/17/2013

JERUSALEM, April 17, 2013 /PRNewswire/ --

SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of technologies that reduces errors and eliminates pain during the administration of prescription medications, announced today that the company intends to hire a Project Manager to oversee and implement a marketing strategy to commercialize its newly acquired painless injection device.

The company's new technology is fully approved by the Federal Drug Administration (FDA), and has demonstrated itself to be safe and effective in actively reducing pain during the administration of blood tests, lanching and injections - a daily reality for many during ongoing medical care.

Both EZJect and Quickool - the newly acquired technologies - received FDA approval for commercialization in 2007.

"To acquire technology that already has FDA approval, is a major step toward full commercialization in the United States," said Akiva Schonfled, Chief Executive Officer of SafeCode Drug Technologies.  "These technologies have applications in hospitals, doctor's offices and clinics, in addition to the at-home, individual care markets. We are confident that with the right project manager in place, we can implement a winning commercialization strategy."

About SafeCode Drug Technologies

SafeCode Drug Technologies is the developer of patent-pending technologies that reduce errors and eliminate pain during the administration of prescription medications. The company's initial technology is voice-activated administration technology that ensures the proper medication is administered to the proper patient. The company's newly acquired EZJect technology eliminates pain during blood tests and injections.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
CEO, Akiva Schonfled
+9722-582-0394


'/>"/>
SOURCE Safecode Drug Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
2. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
3. SafeCode Drug Technologies Corp Signs an Agreement With INTOVISION PRODUCT DEVELOPMENT & DESIGN (An Israeli Product Development Co) to Manufacturers the Worlds First Voice Recognition Drug Safety Application Prototype
4. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
5. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
6. SafeCode Drug Technologies Corp. in Negotiations With Manufacturers to Develop Prototype
7. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
8. Antibody Technologies and Attrition Rates - An Industry Analysis 2013
9. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
10. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
11. Multisorb Technologies Non-Toxic StabilOx Oxygen Absorbing Canisters Provide Worry-Free Drug Stability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a ... he has leant his presence to an educational purpose as the host of the ... one being cancer. In a recent episode, the series focuses on thyroid cancer. , ...
Breaking Medicine News(10 mins):